Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Schiffl

Showing results (31-40 of 141) with videos related to

Pageof 15
Sort By:
Nephron|January 13, 1999
Angiotensin-converting enzyme inhibitors but not angiotensin II AT 1 receptor antagonists affect erythropoiesis in patients with anemia of end-stage renal diseaseH Schiffl, S M Lang
The International Journal of Artificial Organs|July 1, 1997
Membranes in ARF: a procrustean hypothesis or scientific advance?H Schiffl, S M Lang
Lancet (London, England)|December 16, 1998
Losartan and anaemia of end-stage renal diseaseS M Lang, H Schiffl
European Journal of Medical Research|March 24, 1997
Hypertension induced by recombinant human erythropoietin (rHU-EPO) can be prevented by indomethacin. Pathogenetic role of cytosolic calciumH Schiffl, S M Lang
International Urology and Nephrology|June 20, 2025
Long-term renal consequences of COVID-19. Emerging evidence and unanswered questionsS M Lang, H Schiffl
Indian Journal of Nephrology|December 17, 2013
Current practice of conventional intermittent hemodialysis for acute kidney injuryH Schiffl, S M Lang
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 23, 1999
Effect of dialyser biocompatibility on recovery from acute renal failure after cadaveric renal transplantationS M Lang, H Schiffl
Nephron|January 1, 1980
Human urinary fluoride excretion as influenced by renal functional impairmentH H Schiffl, U Binswanger
Lancet (London, England)|October 31, 2006
Renal replacement therapy in acute renal failureH Schiffl, S M Lang
Nephron|July 18, 2002
Ultrapure dialysis fluid lowers the cardiovascular morbidity in patients on maintenance hemodialysis by reducing continuous microinflammationS R Lederer, H Schiffl
Pageof 15

Showing results (31-40 of 141) with videos related to

Sort By:
Pageof 15
Nephron|January 13, 1999
Angiotensin-converting enzyme inhibitors but not angiotensin II AT 1 receptor antagonists affect erythropoiesis in patients with anemia of end-stage renal diseaseH Schiffl, S M Lang
The International Journal of Artificial Organs|July 1, 1997
Membranes in ARF: a procrustean hypothesis or scientific advance?H Schiffl, S M Lang
Lancet (London, England)|December 16, 1998
Losartan and anaemia of end-stage renal diseaseS M Lang, H Schiffl
European Journal of Medical Research|March 24, 1997
Hypertension induced by recombinant human erythropoietin (rHU-EPO) can be prevented by indomethacin. Pathogenetic role of cytosolic calciumH Schiffl, S M Lang
International Urology and Nephrology|June 20, 2025
Long-term renal consequences of COVID-19. Emerging evidence and unanswered questionsS M Lang, H Schiffl
Indian Journal of Nephrology|December 17, 2013
Current practice of conventional intermittent hemodialysis for acute kidney injuryH Schiffl, S M Lang
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 23, 1999
Effect of dialyser biocompatibility on recovery from acute renal failure after cadaveric renal transplantationS M Lang, H Schiffl
Nephron|January 1, 1980
Human urinary fluoride excretion as influenced by renal functional impairmentH H Schiffl, U Binswanger
Lancet (London, England)|October 31, 2006
Renal replacement therapy in acute renal failureH Schiffl, S M Lang
Nephron|July 18, 2002
Ultrapure dialysis fluid lowers the cardiovascular morbidity in patients on maintenance hemodialysis by reducing continuous microinflammationS R Lederer, H Schiffl
Pageof 15